Piper Jaffray initiates coverage on Peregrine Pharmaceuticals (NASDAQ: PPHM) with a Overweight. PT $2.50.
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Shares of Peregrine Pharmaceuticals closed at $1.26 yesterday, with a 52 week range of $0.39-$5.50.
Mr. Duncan has a great deal of credibility. It's a nice win!
AF is in denial. When is his next hit piece coming out? Or is he too busy trying to refute other Bio stocks that are about launch their FDA approved product. (ARNA comes to mind)